Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
The Ontario Institute For Cancer Research (Oicr) is currently prosecuting patent applications in the Biotechnology & Pharmaceuticals technology area. The portfolio features 4 pending office actions, indicating active development of its intellectual property. These actions are situated within 3 distinct art units, which shows that the institute's biological and pharmaceutical innovations are being reviewed by 3 different specialized groups of examiners. This requires the management of technical dialogues across multiple specialized divisions within the patent office.
The prosecution involves 4 distinct examiners, meaning that every pending office action is being reviewed by a different person. ELENISTE, PIERRE PAUL is identified as the busiest examiner for this portfolio, currently responsible for 1 pending office action. Since the number of examiners equals the number of pending actions, the workload is evenly distributed across the assigned staff. Practitioners should be prepared to address the specific technical requirements of 3 different art units while managing the individual expectations of the 4 different examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.5% | +31.2% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838651 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | ELENISTE, PIERRE PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17612695 | PAN-CANCER TRANSCRIPTIONAL SIGNATURE | GOLDBERG, JEANINE ANNE | 366d overdue |
| 18838651 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | ELENISTE, PIERRE PAUL | — |
| 18288219 | SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | NESTOR, DONNA MICHELLE | — |
| 18288213 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | RZECZYCKI, PHILLIP MATTHEW | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1625 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838651 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | ELENISTE, PIERRE PAUL | — | §103§112 | Non-Final OA | — | Pending | Aug 15, 2024 |
| 18288219 | SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | NESTOR, DONNA MICHELLE | 1627 | §103DP | Final Rejection | — | Pending | Oct 25, 2023 |
| 18288213 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Final Rejection | — | Pending | Oct 25, 2023 |
| 17612695 | PAN-CANCER TRANSCRIPTIONAL SIGNATURE | GOLDBERG, JEANINE ANNE | 1682 | §112 | Non-Final OA | 366d overdue | Pending | Nov 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial